CVRx price target raised to $20 from $16 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on CVRx (CVRX) to $20 from $16 and keeps an Overweight rating on the shares following quarterly results. There were no major surprises outside of opex spending, which is higher than some had hoped for in Q4, which is expected to continue in 2025, the firm says. Piper believes an early glimpse of traction against investments and the company’s new commercial strategy is evident by the solid top-line performance in Q4 and high number of units per center. Looking forward, it anticipates Barostim will continue to drive nice top-line growth for years to come for this unique cardio name. Piper views the stock’s weakness following the print as a nice entry point.